Stock Analiz

Valion Bio, Inc. VBIO

Biotechnology: Electromedical & Electrotherapeutic Apparatus · IPO 2021 · data as of November 13, 2026

$0.53Market cap $1M
Open the interactive analysis →

Valion Bio, Inc. (VBIO) is a healthcare company listed in the US with a market value of about $1M.

Its overall Stock Analiz score is 0.2 out of 5 (weak). The strongest part is financial health (1/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -111%.

About Valion Bio

Valion Bio is listed in the US and classified in biotechnology: electromedical & electrotherapeutic apparatus, IPO year 2021. Revenue went from $1M in 2021 to $780000 in 2024, a decline of about 14.7% a year. It was profitable in 0 of the last 5 years in our data. Its share count rose by 20198% over three years (dilution for shareholders).

Score: 0.2 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B0.3
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-1286.1%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-662.6%
ROIC (5-yr avg.)-111.0%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 5 years

Fiscal year20252024202320222021
Revenue—$780000$1M$2M$1M
Net income-$9M-$6M-$8M-$10M-$8M
Free cash flow-$7M-$6M-$9M-$9M—
EPS (diluted)$-7.84$-19.68$-176.80$-1773.42$-4128.90
Net margin—-725.0%-701.0%-548.7%-675.7%
ROIC-26.8%-139.5%-164.9%-191.8%-31.8%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Valion Bio pay a dividend?

Not currently.

Is Valion Bio a good stock to buy?

We do not give buy or sell advice. Valion Bio scores 0.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.